<DOC>
	<DOCNO>NCT01233609</DOCNO>
	<brief_summary>The objective study evaluate efficacy Valproic Acid ( VPA ) slow progression visual function loss and/or restore visual function patient Autosomal Dominant Retinitis Pigmentosa ( RP ) collect safety tolerability information .</brief_summary>
	<brief_title>Trial Oral Valproic Acid Retinitis Pigmentosa</brief_title>
	<detailed_description>Retinitis Pigmentosa ( RP ) incurable untreatable group heterogeneous retinal degenerative disease cause severe visual loss . There currently therapeutic substantially slow progression disease , certainly none restore vision RP patient . The Valproic Acid ( VPA ) study design six-site , interventional , prospective , randomize , placebo control , double-blinded study 90 participant evaluate efficacy oral Valproic Acid slow progression visual function loss and/or restore visual function patient Autosomal Dominant RP genetic mutation collect safety tolerability information . Patients participate study randomize either placebo VPA 1:1 ratio .</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Understand/sign IRBapproved study inform consent document . 2 . Age great equal 18 year , upper age limit 3 . Males nonchild bearing female must weigh ≥40 Kg ≤158.9 Kg ; Females child bear potential must weigh ≥40 Kg ≤74.9 Kg . 4 . Diagnosis Retinitis Pigmentosa ( RP ) . 5 . Visual acuity great equal 35 letter least one eye measure EVAETDRS ( equivalent 20/200 Snellen chart ) . 6 . Genotyped autosomal dominant form RP . 7 . Female subject childbearing potential male subject able father child must ( partner ) hysterectomy vasectomy , completely abstinent intercourse must commit practice least two acceptable method contraception minimize chance pregnancy study 13 week period stop study drug . 8 . Female subject childbearing potential must negative urine pregnancy test study entry throughout duration study . 9 . Willingness comply protocol . 1 . Medical problem make consistent followup treatment period unlikely ( e.g . stroke , severe MI , end stage malignancy ) , general poor medical risk systemic disease active uncontrolled infection . 2 . Other retinal disease : Glaucoma , retinal inflammatory disease ( CME allowable ) , cataract bad +2 NS , herpes simplex virus eye . 3 . Intact visual field 5⁰ less . 4 . Subject unable provide reliable perimetry measurement eye static kinetic visual field , determine Reading Center . 5 . Diabetes . 6 . History cancer ( nonmelanoma skin cancer ) diagnose , require treatment within past 2 year . 7 . A hemoglobin concentration , platelet count absolute neutrophil count lower limit normal study entry . 8 . Suspected liver dysfunction determine liver function value elevate upper limit normal . 9 . History pancreatitis clinical feature and/or laboratory abnormality last 12 month . 10 . Renal dysfunction base serum creatinine , ( MDRD ) equation . 11 . Urea cycle disorder . 12 . History neurological condition include epilepsy , history brain injury , encephalitis , organic brain syndrome . 13 . History schizophrenia , schizoaffective disorder , bipolar disorder , suicidality organic mental disorder . 14 . Currently receive valproic acid anticonvulsant . 15 . Sensitive ever allergic reaction valproic Acid . 16 . Sensitive ever allergic reaction peanut peanut oil inactive ingredient valproic acid capsule placebo . 17 . Has take one disallow drug least 2 week prior randomization . 18 . Pregnant woman . 19 . Lactating mother breast feed baby . 20 . RP patient involve clinical trial within last 3 month . 21 . Require enrollment consent legally authorize representative . 22 . Persons unable read allow consent others participate study . 23 . The potential participant life household current participant protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>retinitis pigmentosa</keyword>
	<keyword>valproic acid</keyword>
	<keyword>visual field</keyword>
</DOC>